Skip to main content
Erschienen in: Surgery Today 2/2021

18.08.2020 | Original Article

Elemental diet therapy plays a significant role in preventing surgical recurrence of Crohn’s disease in the era of biologics

verfasst von: Masaru Shinozaki, Tadashi Yokoyama, Naoto Saigusa, Hajime Sato, Kentaro Yazawa, Giichiro Tsurita, Tomohiro Kurokawa, Keisuke Hata, Yasuhisa Yokoyama

Erschienen in: Surgery Today | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Most patients with Crohn’s disease (CD) experience surgical recurrence. In this era of novel therapies, we conducted this study to clarify which treatments effectively decrease the risk of surgical recurrence in patients with CD.

Methods

The subjects of this retrospective study were 37 patients with CD. We created cumulative surgery rate curves and performed univariate and multivariate analyses.

Results

Univariate analysis revealed that patients who consumed an elemental diet (ED; ≥ 900 kcal/day), anti-tumor necrosis factor-alpha, and thiopurines had a significantly better prognosis than those who did not (p = 0.011, p = 0.025, and p = 0.0080, respectively). Multivariate analysis revealed that ED therapy and thiopurines were independent significant factors for controlling surgical recurrence (p = 0.046 and p = 0.032, respectively). Additional analyses showed that the most promising ED therapeutic dose was ≥ 1200 kcal/day, while an ED therapeutic dose of ≥ 900 kcal/day was acceptable.

Conclusions

Although univariate analyses revealed that all three treatment strategies had significant effects on surgical recurrence in patients with CD, multivariate analysis revealed that only ED therapy was significantly associated with surgical recurrence rates. Thus, ED therapy plays an important role in the management of CD, even in the era of biological therapies.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Frolkis AD, Lipton DS, Fiest KM, Negrón ME, Dykeman J, deBruyn J, et al. Cumulative incidence of second intestinal resection in Crohn's disease: a systematic review and meta-analysis of population-based studies. Am J Gastroenterol. 2014;109:1739–48.PubMed Frolkis AD, Lipton DS, Fiest KM, Negrón ME, Dykeman J, deBruyn J, et al. Cumulative incidence of second intestinal resection in Crohn's disease: a systematic review and meta-analysis of population-based studies. Am J Gastroenterol. 2014;109:1739–48.PubMed
2.
Zurück zum Zitat Gionchetti P, Dignass A, Danese S, Magro Dias FJ, Rogler G, Lakatos PL, ECCO. 3rd European Evidence-based Consensus on the Diagnosis, and Management of Crohn’s Disease, et al. Part 2: Surgical Management and Special Situations. J Crohns Colitis. 2016;2017(11):135–49. Gionchetti P, Dignass A, Danese S, Magro Dias FJ, Rogler G, Lakatos PL, ECCO. 3rd European Evidence-based Consensus on the Diagnosis, and Management of Crohn’s Disease, et al. Part 2: Surgical Management and Special Situations. J Crohns Colitis. 2016;2017(11):135–49.
3.
Zurück zum Zitat Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol. 2018;113:481–517.CrossRef Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol. 2018;113:481–517.CrossRef
4.
Zurück zum Zitat Ruemmele FM, Veres G, Kolho KL, Griffiths A, Levine A, Escher JC, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. J Crohns Colitis. 2014;8:1179–207.CrossRef Ruemmele FM, Veres G, Kolho KL, Griffiths A, Levine A, Escher JC, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. J Crohns Colitis. 2014;8:1179–207.CrossRef
5.
Zurück zum Zitat Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–9.CrossRef Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–9.CrossRef
6.
Zurück zum Zitat Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52–655.CrossRef Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52–655.CrossRef
7.
Zurück zum Zitat Lopes S, Rodrigues-Pinto E, Andrade P, Afonso J, Baron TH, et al. Endoscopic balloon dilation of Crohn’s disease strictures-safety, efficacy and clinical impact. World J Gastroenterol. 2017;23:7397–406.CrossRef Lopes S, Rodrigues-Pinto E, Andrade P, Afonso J, Baron TH, et al. Endoscopic balloon dilation of Crohn’s disease strictures-safety, efficacy and clinical impact. World J Gastroenterol. 2017;23:7397–406.CrossRef
8.
Zurück zum Zitat Ohara N, Mizushima T, Iijima H, Takahashi H, Hiyama S, Haraguchi N, et al. Adherence to an elemental diet for preventing postoperative recurrence of Crohn’s disease. Surg Today. 2017;47:1519–25.CrossRef Ohara N, Mizushima T, Iijima H, Takahashi H, Hiyama S, Haraguchi N, et al. Adherence to an elemental diet for preventing postoperative recurrence of Crohn’s disease. Surg Today. 2017;47:1519–25.CrossRef
9.
Zurück zum Zitat Reese GE, Nanidis T, Borysiewicz C, Yamamoto T, Orchard T, Tekkis PP. The effect of smoking after surgery for Crohn’s disease: a meta-analysis of observational studies. Int J Colorectal Dis. 2008;23:1213–21.CrossRef Reese GE, Nanidis T, Borysiewicz C, Yamamoto T, Orchard T, Tekkis PP. The effect of smoking after surgery for Crohn’s disease: a meta-analysis of observational studies. Int J Colorectal Dis. 2008;23:1213–21.CrossRef
10.
Zurück zum Zitat Draper NR, Smith H. Selecting the “best” regression equation. In: Applied regression analysis. 3rd ed., Ney York: Wiley; 1998. p. 327–68. Draper NR, Smith H. Selecting the “best” regression equation. In: Applied regression analysis. 3rd ed., Ney York: Wiley; 1998. p. 327–68.
11.
Zurück zum Zitat Hess KR. Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat Med. 1995;14:1707–23.CrossRef Hess KR. Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat Med. 1995;14:1707–23.CrossRef
12.
Zurück zum Zitat Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749–53.CrossRef Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749–53.CrossRef
13.
Zurück zum Zitat Yamamoto T, Nakahigashi M, Saniabadi AR, Iwata T, Maruyama Y, Umegae S, et al. Impacts of long-term enteral nutrition on clinical and endoscopic disease activities and mucosal cytokines during remission in patients with Crohn’s disease: a prospective study. Inflamm Bowel Dis. 2007;13:1493–501.CrossRef Yamamoto T, Nakahigashi M, Saniabadi AR, Iwata T, Maruyama Y, Umegae S, et al. Impacts of long-term enteral nutrition on clinical and endoscopic disease activities and mucosal cytokines during remission in patients with Crohn’s disease: a prospective study. Inflamm Bowel Dis. 2007;13:1493–501.CrossRef
14.
Zurück zum Zitat Hirai F1, Ishihara H, Yada S, Esaki M, Ohwan T, Nozaki R, et al. Effectiveness of concomitant enteral nutrition therapy and infliximab for maintenance treatment of Crohn’s disease in adults. Dig Dis Sci. 2013;58:1329–34.CrossRef Hirai F1, Ishihara H, Yada S, Esaki M, Ohwan T, Nozaki R, et al. Effectiveness of concomitant enteral nutrition therapy and infliximab for maintenance treatment of Crohn’s disease in adults. Dig Dis Sci. 2013;58:1329–34.CrossRef
15.
Zurück zum Zitat Kusaka J, Shiga H, Kuroha M, Kimura T, Kakuta Y, Endo K, et al. Risk factors associated with postoperative recurrence and repeat surgery in Japanese patients with Crohn’s disease. Int J Colorectal Dis. 2017;32:1407–13.CrossRef Kusaka J, Shiga H, Kuroha M, Kimura T, Kakuta Y, Endo K, et al. Risk factors associated with postoperative recurrence and repeat surgery in Japanese patients with Crohn’s disease. Int J Colorectal Dis. 2017;32:1407–13.CrossRef
16.
Zurück zum Zitat Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362:1383–95.CrossRef Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362:1383–95.CrossRef
17.
Zurück zum Zitat Mowat C, Arnott I, Cahill A, Smith M, Ahmad T, Subramanian S, et al. Mercaptopurine versus placebo to prevent recurrence of Crohn’s disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial. Lancet Gastroenterol Hepatol. 2016;1:273–82.CrossRef Mowat C, Arnott I, Cahill A, Smith M, Ahmad T, Subramanian S, et al. Mercaptopurine versus placebo to prevent recurrence of Crohn’s disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial. Lancet Gastroenterol Hepatol. 2016;1:273–82.CrossRef
18.
Zurück zum Zitat Yang KM, Yu CS, Lee JL, Kim CW, Yoon YS, Park IJ, et al. Risk factors for postoperative recurrence after primary bowel resection in patients with Crohn’s disease. World J Gastroenterol. 2017;23:7016–24.CrossRef Yang KM, Yu CS, Lee JL, Kim CW, Yoon YS, Park IJ, et al. Risk factors for postoperative recurrence after primary bowel resection in patients with Crohn’s disease. World J Gastroenterol. 2017;23:7016–24.CrossRef
Metadaten
Titel
Elemental diet therapy plays a significant role in preventing surgical recurrence of Crohn’s disease in the era of biologics
verfasst von
Masaru Shinozaki
Tadashi Yokoyama
Naoto Saigusa
Hajime Sato
Kentaro Yazawa
Giichiro Tsurita
Tomohiro Kurokawa
Keisuke Hata
Yasuhisa Yokoyama
Publikationsdatum
18.08.2020
Verlag
Springer Singapore
Erschienen in
Surgery Today / Ausgabe 2/2021
Print ISSN: 0941-1291
Elektronische ISSN: 1436-2813
DOI
https://doi.org/10.1007/s00595-020-02112-5

Weitere Artikel der Ausgabe 2/2021

Surgery Today 2/2021 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.